Breast Cancer Clinical Trial
— ATNECOfficial title:
ATNEC - Axillary Management in T1-3N1M0 Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases at Presentation After Neoadjuvant Chemotherapy
The aim of this study is to assess whether, omitting further axillary treatment (ALND and ART) for patients with early stage breast cancer and axillary nodal metastases on needle biopsy, who after NACT have no residual cancer in the lymph nodes on sentinel node biopsy, is non-inferior to axillary treatment in terms of disease free survival (DFS) and results in reduced risk of lymphoedema at 5 years.
Status | Recruiting |
Enrollment | 1900 |
Est. completion date | February 28, 2030 |
Est. primary completion date | February 28, 2030 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - cT1-3N1M0 breast cancer at diagnosis (prior to NACT) by American Joint Committee on Cancer (AJCC) staging 8th edition - Patients with occult primary breast cancer (no identifiable invasive cancer in the breast) with FNA or core biopsy proven nodal metastases are also eligible for the study. - Fine-needle aspiration (FNA) or core biopsy confirmed axillary nodal metastases at presentation - Oestrogen receptor and HER2 status evaluated on primary tumour - Received standard NACT as per local guidelines (Patients undergoing neoadjuvant endocrine therapy as part of another clinical trial are eligible) - Imaging of the axilla, as required, to assess response to NACT (per local guidelines) - Undergo a dual tracer sentinel node biopsy (SNB) after NACT with at least 3 nodes removed in total (sentinel nodes and marked node). - If a single tracer SNB is performed, the patient is eligible only if the involved node is marked before or during NACT, and at least 3 nodes (including the marked node) are removed during sentinel node biopsy. - If the node is not marked, or the marked node is not removed, the patient is eligible only if the histology report shows evidence of down-staging with complete pathological response e.g. fibrosis or scarring in at least one node and at least 3 nodes removed. - If fewer than 3 nodes are found on histology, the patient is eligible only if BOTH points a) and b) below, are met: 1. involved node was marked and removed during SNB; and 2. removed marked node shows evidence of downstaging on histology e.g. fibrosis or scarring. - If the sentinel node(s) cannot be localised on SNB: axillary node sampling should be performed, the patient will be eligible if at least 3 nodes are removed (including the marked node). - No evidence of nodal metastases post NACT (isolated tumour cells, micro or macro metastasis) - Patients with complete pathological response in the axilla but residual disease in the breast post NACT are eligible for the study. Exclusion Criteria: - Bilateral synchronous invasive breast cancer - Sentinel node biopsy prior to NACT - Previous axillary surgery on the same body side as the scheduled targeted sampling - Any previous cancer within 5 years or concomitant malignancy except - basal or squamous cell carcinoma of the skin - in situ carcinoma of the cervix - in situ melanoma - contra- or ipsilateral in situ breast cancer |
Country | Name | City | State |
---|---|---|---|
United Kingdom | NHS Grampian | Aberdeen | |
United Kingdom | Ashford and St Peter's Hospitals NHS Foundation Trust | Ashford | |
United Kingdom | Tameside and Glossop Integrated Care NHS Foundation Trust | Ashton-under-Lyne | |
United Kingdom | NHS Ayrshire and Arran | Ayr | |
United Kingdom | Belfast Health and Social Care Trust | Belfast | |
United Kingdom | Sandwell and West Birmingham NHS Trust | Birmingham | |
United Kingdom | University Hospitals Birmingham NHS Foundation Trust | Birmingham | |
United Kingdom | Bolton NHS Foundation Trust | Bolton | |
United Kingdom | Bradford Teaching Hospitals NHS Foundation Trust | Bradford | |
United Kingdom | University Hospitals Sussex NHS Foundation Trust | Brighton | |
United Kingdom | North Bristol NHS Trust | Bristol | |
United Kingdom | East Lancashire Hospitals NHS Trust | Burnley | |
United Kingdom | Frimley Health NHS Foundation Trust | Camberley | Gu16 7uj |
United Kingdom | Cambridge University Hospitals NHS Foundation Trust | Cambridge | |
United Kingdom | North Cumbria Integrated Care NHS Foundation Trust | Carlisle | Ca2 7hy |
United Kingdom | Countess of Chester Hospital NHS Trust | Chester | |
United Kingdom | Mid Cheshire NHS Foundation Trust | Crewe | |
United Kingdom | County Durham and Darlington NHS Foundation Trust | Darlington | |
United Kingdom | University Hospitals of Derby and Burton NHS Foundation Trust | Derby | |
United Kingdom | Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust | Doncaster | |
United Kingdom | The Dudley Group NHS Foundation Trust | Dudley | |
United Kingdom | NHS Dumfries and Galloway | Dumfries | |
United Kingdom | NHS Fife | Dunfermline | |
United Kingdom | NHS Lanarkshire | East Kilbride | |
United Kingdom | NHS Lothian | Edinburgh | |
United Kingdom | Royal Devon and Exeter NHS Foundation Trust | Exeter | |
United Kingdom | Gateshead Health NHS Foundation Trust | Gateshead | |
United Kingdom | James Paget University Hospitals NHS Foundation Trust | Great Yarmouth | Nr31 6la |
United Kingdom | Harrogate and District NHS Foundation Trust | Harrogate | |
United Kingdom | Wye Valley NHS Trust | Hereford | |
United Kingdom | Buckinghamshire Healthcare NHS Trust | High Wycombe | |
United Kingdom | Calderdale and Huddersfield NHS Foundation Trust | Huddersfield | |
United Kingdom | Hull University Teaching Hospitals NHS Trust | Hull | |
United Kingdom | NHS Highland | Inverness | Iv2 3uj |
United Kingdom | East Suffolk and North Essex NHS Foundation Trust | Ipswich | |
United Kingdom | Chelsea and Westminster Hospital NHS Foundation Trust | Isleworth | |
United Kingdom | Airedale NHS Foundation Trust | Keighley | Bd20 6td |
United Kingdom | University Hospitals of Morecambe Bay NHS Foundation Trust | Lancaster | |
United Kingdom | NHS Forth Valley | Larbert | |
United Kingdom | Leeds Teaching Hospitals NHS Trust | Leeds | |
United Kingdom | University Hospitals of Leicester NHS Trust | Leicester | |
United Kingdom | United Lincolnshire Hospitals NHS Trust | Lincoln | |
United Kingdom | Hywel Dda University Health Board | Llanelli | |
United Kingdom | Imperial College Healthcare NHS Trust | London | |
United Kingdom | King's College Hospital NHS Foundation Trust | London | |
United Kingdom | North Middlesex University Hospital NHS Trust | London | |
United Kingdom | Royal Free London NHS Foundation Trust | London | |
United Kingdom | The Royal Marsden NHS Foundation Trust | London | |
United Kingdom | University College London Hospitals NHS Foundation Trust | London | |
United Kingdom | Bedfordshire Hospitals NHS Foundation Trust | Luton | |
United Kingdom | East Cheshire NHS Trust | Macclesfield | Sk10 3bl. |
United Kingdom | Manchester University NHS Foundation Trust | Manchester | |
United Kingdom | NHS Borders | Melrose | |
United Kingdom | South Tees Hospitals NHS Foundation Trust | Middlesbrough | |
United Kingdom | Milton Keynes University Hospital NHS Trust | Milton Keynes | |
United Kingdom | Newcastle Upon Tyne Hospitals NHS Foundation Trust | Newcastle Upon Tyne | |
United Kingdom | Oxford University Hospitals NHS Foundation Trust | Oxford | |
United Kingdom | NHS Greater Glasgow and Clyde | Paisley | |
United Kingdom | University Hospitals Plymouth NHS Trust | Plymouth | |
United Kingdom | St Helens and Knowsley Teaching Hospitals NHS Trust | Prescot | |
United Kingdom | Royal Berkshire NHS Foundation Trust | Reading | Rg1 5an |
United Kingdom | The Rotherham NHS Foundation Trust | Rotherham | |
United Kingdom | The Shrewsbury and Telford Hospitals NHS Trust | Shrewsbury | Sy3 8xq |
United Kingdom | West Hertfordshire Hospitals NHS Trust | St Albans | |
United Kingdom | East and North Hertfordshire NHS Foundation Trust | Stevenage | |
United Kingdom | North Tees and Hartlepool NHS Foundation Trust | Stockton-on-Tees | |
United Kingdom | University Hospitals of North Midlands NHS Trust | Stoke-on-Trent | |
United Kingdom | Somerset NHS Foundation Trust | Taunton | |
United Kingdom | Croydon Health Services NHS Trust | Thornton Heath | |
United Kingdom | Royal Cornwall Hospitals NHS Trust | Truro | |
United Kingdom | Mid Yorkshire Hospitals NHS Trust | Wakefield | |
United Kingdom | Mid and South Essex NHS Foundation Trust | Westcliff-on-Sea | |
United Kingdom | Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust | Wigan | |
United Kingdom | Clatterbridge Cancer Centre NHS Foundation Trust | Wirral | |
United Kingdom | Wirral University Teaching Hospital NHS Foundation Trust | Wirral | |
United Kingdom | The Royal Wolverhampton NHS Trust | Wolverhampton | |
United Kingdom | Yeovil District Hospital NHS Trust | Yeovil | |
United Kingdom | York and Scarborough Teaching Hospitals NHS Foundation Trust | York |
Lead Sponsor | Collaborator |
---|---|
University Hospitals of Derby and Burton NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease free survival (DFS) | DFS calculated as the time from randomisation until the date of first event of either a loco-regional invasive breast cancer relapse, distant relapse, ipsilateral or contralateral new invasive primary breast cancer or death by any cause or the censor date. | 5 years | |
Primary | Patient reported lymphoedema | Lymphoedema is self-reported based on two items from the validated Lymphoedema and Breast Cancer Questionnaire (arm "swelling now" and arm "heaviness in the past year"). Lymphoedema is defined as 'yes' to both questions. | 5 years | |
Secondary | Arm function | Arm function will be assessed using shortened version of the Disability of the Arm, Shoulder and Hand (DASH), the 11-item QuickDASH questionnaire. Physical disability is defined as a change from baseline in the QuickDASH score of at least 14 points. | 5 years | |
Secondary | Health related quality of life: EQ-5D-5L | Health related quality of life will be assessed with EQ-5D-5L | 5 years | |
Secondary | Axillary recurrence free interval | Axillary recurrence free interval, calculated from the date of randomisation to the date of axillary recurrence or the censor date. | 5 years | |
Secondary | Overall survival | Overall survival calculated as the time from randomisation until the date of death by any cause or the censor date. | 5 years | |
Secondary | Local (breast or chest wall) recurrence | Number of participants with local (breast or chest wall) recurrence | 5 years | |
Secondary | Regional (nodal) recurrence | Number of participants with regional (nodal) recurrence | 5 years | |
Secondary | Distant metastasis | Number of participants with distant metastasis. | 5 years | |
Secondary | Contralateral breast cancer | Number of participants with contralateral breast cancer. | 5 years | |
Secondary | Non-breast cancer | Number of participants with non-breast cancer | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |